{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:02:39Z","timestamp":1756461759135,"version":"3.44.0"},"reference-count":11,"publisher":"BMJ","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[1994,1]]},"abstract":"<jats:p>Each year in the United Kingdom about 250 000 people die from acute myocardial infarction, other ischaemic heart disease or stroke. Many will already have evidence of established vascular disease that predisposes to such an event - such as angina, peripheral vascular disease, atrial fibrillation, transient ischaemic attacks or a previous myocardial infarction or stroke. Others will have risk factors such as hypertension, diabetes mellitus or hyperlipidaemia, but the stroke or heart attack is the first evidence of established vascular disease. Aspirin was first discovered to have antiplatelet properties 30 years ago and since then many randomised clinical trials have sought to determine whether it (or other antiplatelet agents) can protect patients from heart attack or stroke. In this article we review the evidence and update our earlier conclusions on stroke,1 myocardial infarction,2 and unstable angina,3 arguing that aspirin should be widely used to reduce cardiovascular morbidity and mortality in certain high-risk patients.<\/jats:p>","DOI":"10.1136\/dtb.1994.3211","type":"journal-article","created":{"date-parts":[[2007,10,22]],"date-time":"2007-10-22T10:38:46Z","timestamp":1193049526000},"page":"1-3","source":"Crossref","is-referenced-by-count":6,"title":["Aspirin to prevent heart attack or stroke"],"prefix":"10.1136","volume":"32","member":"239","published-online":{"date-parts":[[1994,1,1]]},"reference":[{"key":"2025082700074297000_32.1.1.1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/dtb.23.3.9","article-title":"Management of stroke: 12 hours to 2 months","volume":"23","year":"1985","journal-title":"DTB"},{"key":"2025082700074297000_32.1.1.2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/dtb.25.5.17","article-title":"Aspirin and myocardial infarction","volume":"25","year":"1987","journal-title":"DTB"},{"key":"2025082700074297000_32.1.1.3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/dtb.28.3.9","article-title":"The management of unstable angina","volume":"28","year":"1990","journal-title":"DTB"},{"key":"2025082700074297000_32.1.1.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(89)80010-0"},{"key":"2025082700074297000_32.1.1.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6618.320"},{"key":"2025082700074297000_32.1.1.6","doi-asserted-by":"crossref","unstructured":"Antiplatelet Trialists' Collaborative Group. Collaborative overview of randomised trials of antiplatelet therapy. Part I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients Br Med J 1994; 308 [in press].","DOI":"10.1136\/bmj.308.6921.81"},{"key":"2025082700074297000_32.1.1.7","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199110313251801","article-title":"The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30mg vs 283mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"2025082700074297000_32.1.1.8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.12.1044"},{"key":"2025082700074297000_32.1.1.9","first-page":"349","article-title":"ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction","volume-title":"Lancet","volume":"ii","year":"1988"},{"key":"2025082700074297000_32.1.1.10","doi-asserted-by":"crossref","unstructured":"Antiplatelet Trialists' Collaborative Group. Collaborative overview of randomised trials of antiplatelet therapy. Part 2: Maintenance of arterial or vascular graft patency by antiplatelet therapy Br Med J 1994; 308 [in press].","DOI":"10.1136\/bmj.308.6922.159"},{"key":"2025082700074297000_32.1.1.11","doi-asserted-by":"crossref","unstructured":"Antiplatelet Trialists' Collaborative Group. Collaborative overview of randomised trials of antiplatelet therapy. Part 3: Reduction in venous thrombosis and pulmonary embolism observed with antiplatelet prophylaxis among surgical and medical patients Br Med J 1994; 308 [in press].","DOI":"10.1136\/bmj.308.6923.235"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.1994.3211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:07:52Z","timestamp":1756278472000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.1994.3211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,1]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[1994,1,1]]},"published-print":{"date-parts":[[1994,1]]}},"alternative-id":["10.1136\/dtb.1994.3211"],"URL":"https:\/\/doi.org\/10.1136\/dtb.1994.3211","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[1994,1]]}}}